Skip to main content

Advertisement

Open Peer Review Reports for: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
29 Nov 2018 Submitted Original manuscript
17 Jan 2019 Reviewed Reviewer Report - Shuangshuang Fu
21 Jan 2019 Reviewed Reviewer Report - Alice Dragomir
19 Feb 2019 Author responded Author comments - Huan Deng
Resubmission - Version 2
19 Feb 2019 Submitted Manuscript version 2
24 Feb 2019 Reviewed Reviewer Report - Alice Dragomir
8 Mar 2019 Reviewed Reviewer Report - Shuangshuang Fu
12 Mar 2019 Author responded Author comments - Huan Deng
Resubmission - Version 3
12 Mar 2019 Submitted Manuscript version 3
30 Mar 2019 Author responded Author comments - Huan Deng
Resubmission - Version 4
30 Mar 2019 Submitted Manuscript version 4
22 Apr 2019 Author responded Author comments - Huan Deng
Resubmission - Version 5
22 Apr 2019 Submitted Manuscript version 5
5 May 2019 Author responded Author comments - Huan Deng
Resubmission - Version 6
5 May 2019 Submitted Manuscript version 6
Publishing
10 May 2019 Editorially accepted
23 May 2019 Article published 10.1186/s12885-019-5704-3

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement